Abbott Laboratories is grappling with a 4.4% year-over-year decline in its Nutrition segment due to a voluntary recall of certain pediatric powder formulas, which has led to a broader drop in share performance of 1.2%, contrasting with the industry’s sharper decline. In light of this, the company is implementing corrective actions, including the release of limited metabolic nutrition formulas and advising shareholders to be cautious about an unsolicited mini-tender offer from TRC, which offers below market value. Despite these challenges, Abbott is experiencing organic sales growth in other core segments and remains committed to enhancing its health technology offerings.
“Abbott · shares have declined · Zacks Medical - Products industry · -1.2% vs. -23.9%”
“Abbott · pediatric nutrition sales were negatively impacted by · voluntary recall of certain powder formulas”
“Abbott · reported a decline · Nutrition · 4.4% year-over-year on an organic basis”
“Abbott · is releasing · limited quantities of metabolic nutrition formulas · at the request of the U.S. FDA”
“Abbott · will work with · metabolic centers and healthcare providers · to fulfill requests based on need”
“Abbott · has implemented · corrective actions · to address the situation”
“Abbott · committed to working with · the FDA · to address this situation”
“Abbott · said no formula has been distributed that · has tested positive for either bacteria · true”
“Abbott · launched · NeuroSphere myPath digital health app · upgraded version with enhanced functionality”
“Abbott · has · 113,000 colleagues · serving people in more than 160 countries”
“Abbott · shares have declined · over the past year · -1.2%”
“Abbott · pediatric nutrition sales were negatively impacted by · a voluntary recall · certain powder formulas”